Ida Skarping

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Cross Sectional

Neoadjuvant Chemotherapy

Clinical Practice

Top Venues

Acta oncologica (Stockholm, Sweden)

Breast cancer research and treatment

Cancer causes & control : CCC

This page only lists publications with an associated author ORCID identifier.

Publications

Ida Skarping
18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting. Acta oncologica (Stockholm, Sweden) 63 (2024)
Ida Skarping
18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting. Acta oncologica (Stockholm, Sweden) 63 (2024)
Ida Skarping, Julia Ellbrant, Looket Dihge, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Lisa Rydén
Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750). BMC cancer 24 (1) (2024)
Ida Skarping, Julia Ellbrant, Looket Dihge, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Lisa Rydén
Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750). BMC cancer 24 (1) (2024)
Ida Skarping
18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting. Acta oncologica (Stockholm, Sweden) 63 (2024)
Ida Skarping, Julia Ellbrant, Looket Dihge, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Lisa Rydén
Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750). BMC cancer 24 (1) (2024)
Malin Hjärtström, Looket Dihge, Pär-Ola Bendahl, Ida Skarping, Julia Ellbrant, Mattias Ohlsson, Lisa Rydén
Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning: External Validation and Further Model Development. JMIR cancer 9 (2023)
Ida Skarping, Kristoffer Nilsson, Looket Dihge, Adam Fridhammar, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Katarina Steen Carlsson, Lisa Rydén
The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. Breast cancer research and treatment 194 (3) (2022)
Ida Skarping, Stine Blaabjerg Pedersen, Daniel Förnvik, Sophia Zackrisson, Signe Borgquist
The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients. Acta oncologica (Stockholm, Sweden) 61 (6) (2022)
Ida Skarping, Looket Dihge, Pär-Ola Bendahl, Linnea Huss, Julia Ellbrant, Mattias Ohlsson, Lisa Rydén
The NILS Study Protocol: A Retrospective Validation Study of an Artificial Neural Network Based Preoperative Decision-Making Tool for Noninvasive Lymph Node Staging in Women with Primary Breast Cancer (ISRCTN14341750). Diagnostics (Basel, Switzerland) 12 (3) (2022)
Ida Skarping, Daniel Förnvik, Sophia Zackrisson, Signe Borgquist, Lisa Rydén
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer. Breast cancer research and treatment 189 (1) (2021)
Ida Skarping, Daniel Förnvik, Uffe Heide-Jørgensen, Lisa Rydén, Sophia Zackrisson, Signe Borgquist
Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study. Acta oncologica (Stockholm, Sweden) 59 (12) (2020)
Ida Skarping, Daniel Förnvik, Uffe Heide-Jørgensen, Hanna Sartor, Per Hall, Sophia Zackrisson, Signe Borgquist
Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. Cancer causes & control : CCC 32 (3) (2020)
Ida Skarping, Daniel Förnvik, Hanna Sartor, Uffe Heide-Jørgensen, Sophia Zackrisson, Signe Borgquist
Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. BMC cancer 19 (1) (2019)